Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
iShares Biotechnology ETF(IBB)
Top performer 
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for IBB
11/12/2026: IBB (5-star) is a STRONG-BUY. BUY for 12 days. Simulated Profits (-1.35%). Updated daily EoD!
The iShares Biotechnology ETF (IBB) provides broad, market-cap-weighted exposure to the U.S. biotechnology sector, tracking the ICE Biotechnology Index. It is among the most liquid and accessible vehicles for investors looking to capture innovation in drug discovery and healthcare research. While its large-cap focus offers a degree of stability compared to smaller peers, investors must contend with high sector-specific volatility driven by regulatory shifts, clinical trial results, and binary outcomes. The fund is ideal for growth-focused investors who understand the risks associated with the industry and are prepared for potential long-term price fluctuations.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The biotechnology sector is a classic growth-oriented industry, driven by innovation and future earnings potential. |
| Momentum investor | Strong fit while signal remains positive | Biotech stocks often exhibit strong trend-following behavior during periods of sector-wide innovation and positive clinical news. |
| Value investor | Weak fit | Biotechnology companies are often priced on future promise rather than current earnings or book value. |
| Dividend/Income investor | Weak fit | Most companies in this sector reinvest capital into R&D rather than paying dividends to shareholders. |
| Low-risk investor | Weak fit | The sector's inherent volatility due to clinical trials and regulatory risks is unsuitable for low-risk portfolios. |
Investor Profile
Ideal Investor Profile
Growth-oriented investors seeking long-term exposure to scientific and medical innovation who can tolerate significant volatility.
Suitability
Best suited for long-term investors or those looking for strategic sector allocation rather than active intraday trading.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | High | The sector is prone to significant price swings based on clinical trial results and regulatory decisions. |
| Market risk | Medium / high | Broader economic downturns can impact capital availability for biotech companies. |
| Concentration | Medium / high | The fund holds a concentrated portfolio where the performance of a few large firms can significantly influence the fund's return. |
| Tracking/expense | Low | The ETF is well-managed with a stable expense ratio and consistent tracking against its benchmark. |
| Liquidity | Low | High trading volume ensures that investors can buy or sell without substantial slippage. |
| Business/sector quality | High | The success of companies in this sector is binary, often depending on whether drugs gain regulatory approval. |
Sector & Industry Intelligence
This fund is not assigned to one sector.
Risk Analysis
Volatility
IBB historically exhibits higher-than-average market volatility due to the binary nature of pharmaceutical and biotech research.
Market Risk
The fund is highly sensitive to legislative and economic factors that impact the broader healthcare and capital markets.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Industry | Biotechnology Equities | 92 | This provides broad, diversified exposure to the companies driving innovation in drug development and genetic research. |
| Industry | Pharmaceuticals | 6 | Includes large-cap pharmaceutical companies that have significant biotechnology pipelines. |
| Cash/collateral | Cash and Cash Equivalents | 2 | Maintained to facilitate daily fund operations and liquidity management. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type ETF | Historic Profit 43% | Avg. Invested days 72 | Today’s Advisory Strong Buy |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | ETF Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/12/2026 |
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.